Inventiva Management

Management criteria checks 1/4

We currently do not have sufficient information about the CEO.

Key information

Andrew Obenshain

Chief executive officer

€10.8m

Total compensation

CEO salary percentage	1.41%
CEO tenure	less than a year
CEO ownership	n/a
Management average tenure	less than a year
Board average tenure	6.3yrs

Recent management updates

Recent updates

Seeking Alpha • May 15

Inventiva's Speculative Upside Through MASH Is Promising

Summary Inventiva is now essentially a lanifibranor bet. Their prospects hinge on the upcoming Phase 3 NATiV3 readout, which we should get by Q4 2026. In my view, lanifibranor seems relatively differentiated after its Phase 2b results. Management is narrowing its focus solely on this MASH asset. IVA’s balance sheet has sufficient financing to reach that readout. But please bear in mind that it’s a binary outcome. I believe that, if lanifibranor succeeds, the upside could be considerable. Conversely, if they fail, their runway would be tighter with a failed asset. On balance, IVA is the quintessential high-risk, high-reward biotech stock. But, given its promising trial data, the setup is compelling. Read the full article on Seeking Alpha

Seeking Alpha • Jul 08

Inventiva: Solid MASH Program With Potential For Strategic Partnership Advancement

Summary Inventiva S.A. top-line results from phase 3 NATiV3 study, using lanifibranor for the treatment of patients with MASH, expected by 2nd half of 2026. The 4th pass of the safety review of the DMC was conducted, and it was noted that the phase 3 NATiV3 study should continue without modification. The global non-alcoholic steatohepatitis market is expected to reach $48.3 billion by the end of 2035. It could compete against other MASH companies with the use of lanifibranor by establishing several competitive advantages or by combining it with GLP-1 drugs. Read the full article on Seeking Alpha

Seeking Alpha • Feb 22

Inventiva: Biotech To Consider Despite Short NASH Study Enrollment Pause

Summary Enrollment pause in phase III NATiV3 study, using lanifibranor for the treatment of patients with NASH, only expected to last 4 to 6 weeks; Trial to continue on with protocol amendments. Publication of results from phase IIa LEGEND study, using lanifibranor in combination with Jardiance for the treatment of patients with NASH and Type 2 Diabetes, expected Q1 of 2024. The global non-alcoholic steatohepatitis treatment market size is expected to reach $48.3 billion by the end of 2035. Several competitors in NASH, but the company might overcome most with the fact that oral administration can be given; Another option to beat the competition would be through combination treatments such as lanifibranor + Jardiance. Read the full article on Seeking Alpha

Seeking Alpha • Sep 21

Inventiva, Sino Biopharm sign licensing pact to develop, commercialize NASH treatment

France-based clinical-stage biopharma Inventiva (NASDAQ:IVA) on Wednesday said it had entered into a licensing and collaboration agreement with a unit of Chinese pharmaceutical group Sino Biopharm for its non-alcoholic steatohepatitis (NASH) treatment lanifibranor. As per the deal, Inventiva (IVA) will get a $12M upfront payment along with $5M in short term potential milestone payments. IVA will also be eligible to get up to $290M in clinical, regulatory and commercial milestone payments, in addition to tiered royalties. Sino Biopharm will oversee the development and commercialization of lanifibranor in Greater China, IVA said in a statement. IVA's lanifibranor had previously received a breakthrough therapy designation from the U.S. FDA. U.S.-listed shares of IVA -2.8% to $3.82 after hours.

CEO Compensation Analysis

How has Andrew Obenshain's remuneration changed compared to Inventiva's earnings?
Date	Total Compensation	Salary	Company Earnings
Dec 31 2025	€11m	€152k	-€354m

Compensation vs Market: Andrew's total compensation ($USD12.33M) is above average for companies of similar size in the US market ($USD3.54M).

Compensation vs Earnings: Insufficient data to compare Andrew's compensation with company performance.

CEO

Andrew Obenshain (52 yo)

less than a year

Tenure

€10,832,244

Compensation

Mr. Andrew Obenshain serves as Chief Executive Director at Inventiva S.A. since October 01, 2025 and served as its Director. He has been the Director of bluebird bio, Inc. since November 2021 and served as...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Andrew Obenshain	Chief Executive Officer	less than a year	€10.83m	no data
Pierre Broqua	Co-Founder	15.5yrs	€411.80k	1.45% $ 14.6m
Jean Volatier	Executive VP Finance & Corporate Social Responsibility	less than a year	€1.47m	0.098% $ 986.0k
Martine Zimmermann	Executive VP of Regulatory Affairs & Quality Assurance and Head of Regulatory Affairs	1yr	€4.19m	no data
Jason Campagna	President of Research & Development and Chief Medical Officer	1yr	€2.82m	no data
Axel-Sven Malkomes	Chief Financial Officer	less than a year	no data	no data
Susan Coles	Chief Legal Officer	less than a year	no data	no data
Pamela Herbster	Chief People Officer	less than a year	no data	no data
Pascaline Clerc	Executive Vice President of External and Corporate Affairs	2.8yrs	no data	0.0077% $ 77.8k
Nazira Amra	Chief Commercial Strategy Officer	no data	no data	no data

0.8yrs

Average Tenure

59.5yo

Average Age

Experienced Management: IVA's management team is not considered experienced ( 0.8 years average tenure), which suggests a new team.

Board Members

Name	Position	Tenure	Compensation	Ownership
Mark Pruzanski	Independent Chairman	1.6yrs	€14.42m	no data
Annick Schwebig	Independent Director	9.4yrs	€141.90k	0.0013% $ 13.1k
Jean-Louis Junien	Chairman of Scientific Advisory Board	no data	€16.00k	no data
Andrew Shenker	Member of Scientific Advisory Board	6.7yrs	no data	no data
Arun Sanyal	Member of Scientific Advisory Board	5.9yrs	no data	no data
Heinz Maeusli	Independent Director	7.2yrs	€135.60k	no data
Sven Francque	Member of Scientific Advisory Board	no data	no data	no data
Manal Abdelmalek	Member of Scientific Advisory Board	no data	no data	no data
Kenneth Cusi	Member of Scientific Advisory Board	no data	no data	no data
Glen Clack	Member of Scientific Advisory Board	no data	no data	no data
Gérard Zalcman	Scientific Advisory Board Member	no data	no data	no data
Elisabetta Bugianesi	Member of the Scientific Advisory Board	4.5yrs	no data	no data

6.3yrs

Average Tenure

71yo

Average Age

Experienced Board: IVA's board of directors are considered experienced (6.3 years average tenure).

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2026/07/13 08:58
End of Day Share Price	2026/07/13 00:00
Earnings	2025/12/31
Annual Earnings	2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Inventiva S.A. is covered by 23 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Eliana Merle	Barclays
Edward Nash	Canaccord Genuity
Etzer Darout	Guggenheim Securities, LLC

Inventiva Management

Management criteria checks 1/4

Key information

Recent management updates

Inventiva S.A., Annual General Meeting, Jun 30, 2026

Inventiva Announces Executives Changes

Inventiva Announces CEO Changes

Inventiva Announces Executive Appointments

Inventiva Announces the Appointment of Renée Aguiar-Lucander to Its Board of Directors

Inventiva S.A., Annual General Meeting, May 22, 2025

Recent updates

Inventiva S.A. has completed a Follow-on Equity Offering in the amount of $119.999999 million.

Inventiva S.A. announced that it expects to receive €130 million in funding from BlackRock, Inc., Claret Capital Partners Limited

Inventiva S.A., Annual General Meeting, Jun 30, 2026

Inventiva's Speculative Upside Through MASH Is Promising

Inventiva Announces Executives Changes

Inventiva S.A. to Report Fiscal Year 2025 Results on Mar 30, 2026

Inventiva S.A. has completed a Follow-on Equity Offering in the amount of $149.999996 million.

Inventiva S.A. has filed a Follow-on Equity Offering in the amount of $125 million.

Inventiva S.A. has filed a Follow-on Equity Offering in the amount of $100 million.

Inventiva Announces CEO Changes

Inventiva Announces Executive Appointments

Inventiva Announces the Publication in Journal of Hepatology Reports on Results of Lanifibranor Treatment on Liver Sinusoidal Endothelial Cells in Patients with MASLD/MASH and in Preclinical Models of the Disease

Inventiva Announces the Appointment of Renée Aguiar-Lucander to Its Board of Directors

Inventiva Announces the Publication in Clinical Gastroenterology and Hepatology of Its Analysis of New Biomarker Signatures Predictive of Histological Response in Patients with Mash Treated with Lanifibranor

Inventiva S.A., Annual General Meeting, May 22, 2025

Inventiva S.A. and Hepalys Pharma, Inc. Announce the Initiation of the Clinical Development Program of Lanifibranor in Japan

Inventiva S.A. to Report First Half, 2025 Results on Sep 25, 2025

Inventiva to Present Data from the Final Analysis of the Phase 2 Study Evaluating the Combination of Lanifibranor with Empagliflozin in Patients with Mash and T2d At the Aasld the Liver Meeting® Late-Breaker Session

Inventiva Announces the Positive Recommendation of the Fifth DMC of the Nativ3 Phase 3 Clinical Trial with Lanifibranor in Patients with Mash

Inventiva S.A. announced that it expects to receive €348 million in funding from a group of investors

Inventiva: Solid MASH Program With Potential For Strategic Partnership Advancement

Inventiva Announces the Publication in Nature Communications of Additional Results from Native Phase IIb Clinical Trial Demonstrating Improvement of Markers of Cardiometabolic Health in Patients with MASH/NASH Treated with Lanifibranor

Inventiva: Biotech To Consider Despite Short NASH Study Enrollment Pause

Inventiva S.A. Provides Update on its Clinical Trial NATiV3

Inventiva S.A. to Report First Half, 2024 Results on Sep 25, 2024

Inventiva Announces the Randomization of the First Patient in China in the NATiV3 Clinical Trial and Provides an Update on Its Clinical Development Program

Inventiva S.A. to Report Fiscal Year 2023 Results on Mar 27, 2024

Inventiva S.A. to Report Nine Months, 2023 Results on Sep 28, 2023

Inventiva Announces Positive Topline Results from the Investigator-Initiated Phase Ii Clinical Trial Evaluating Lanifibranor in Patients with T2d and NAFLD

Inventiva S.A. Announces Changes to the Clinical Development of Lanifibranor, Including Plans for New Phase III Trial in Patients with NASH and Compensated Cirrhosis